Factors predicting incomplete recovery from relapses in multiple sclerosis: A prospective study

Multiple Sclerosis

Volumn 14, Issue 4, 2008, Pages 485-493

  Leone, Maurizio A ^a,b   Bonissoni, S ^b   Collimedaglia, L ^b   Tesser, F ^c   Calzoni, S ^b   Stecco, A ^a   Naldi, P ^a   Monaco, F ^b  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c SANT'ANDREA HOSPITAL   (Italy)

Author keywords

Multiple sclerosis; Prognosis; Recovery; Relapse

Indexed keywords

OLIGOCLONAL BAND;

ADULT; ARTICLE; BRAIN STEM; CEREBELLUM DISEASE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; FEMALE; FOLLOW UP; FUNCTIONAL DISEASE; HEREDITY; HUMAN; IMAGE ANALYSIS; INFECTION; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT ASSESSMENT; PREDICTION; PROSPECTIVE STUDY; RELAPSE; RISK ASSESSMENT; SEX DIFFERENCE; SYMPTOMATOLOGY; VISUAL DISORDER;

ADULT; AGE OF ONSET; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; RECURRENCE; RISK FACTORS; SEASONS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 46749123864     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458507084650     Document Type: Article

References (34)

1. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003; 126: 770-82.
2. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991; 114: 1057-67.
3. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005; 4: 281-8.
4. Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-60.
5. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528-32.
6. West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006; 67: 809-13.
7. Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Multiple Sclerosis 2003; 9: 260-74.
8. Amato MP, Ponziani G, Bartolozzi ML, Siracusa G. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999; 168: 96-106.
9. Trojano M, Avolio C, Manzari C, Calo A, De Robertis F, Serio G et al. Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 1995; 58: 300-6.
10. Liu C, Blumhardt LD. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Multiple Sclerosis 1999; 5: 22-8.
11. Hickman SJ, Toosy AT, Miszkiel KA, Jones SJ, Altmann DR, MacManus DG et al. Visual recovery following acute optic neuritis-a clinical, electrophysiological and magnetic resonance imaging study. J Neurol 2004; 251: 996-1005.
12. O'Riordan JI, Thompson AJ, Kingsley DP, Pattison C, Hirsch NP, Howard RS et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121: 495-503.
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
14. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
15. Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, Mcdowell F et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965; 122: 552-68.
16. Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ. EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 1992; 55: 671-6.
17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
18. Korteweg T, Tintoré M, Uitdehaag B, Rovira A, Frederiksen J, Miller D et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006; 5: 221-7.
19. SAS Institute Inc., SUGI supplemental library user's guide. Version 8 edition. Cary, NC: SAS Institute, 1999-2001.
20. Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 1951; 11: 1269-75.
21. Butzkueven H, Mechati S, Hoffmann M, Arruda WO, Bacile E, Boz C et al. Is the current trial definition of confirmed disability progression in multiple sclerosis an accurate measure of permanent disease progression? Multiple Sclerosis 2006; 12: S1-S228.
22. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC. Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group. Neurology. 1990; 40: 971-5.
23. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994; 101: 1771-8.
24. Smith KJ, McDonald WI. The pathophysiology of multiple sclerosis: the mechanisms underlying the production of symptoms and the natural history of the disease. Philos Trans R Soc Lond B Biol Sci 1999; 354: 1649-73.
25. Rudick RA, Lee JC, Simon J, Fisher E. Significance of T2 lesions in multiple sclerosis: a 13-year longitudinal study. Ann Neurol 2006; 60: 236-42.
26. Bergamaschi R. Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision. Expert Rev Neurother 2006; 6: 357-64.
27. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000; 343: 1430-8.
28. Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT et al. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Arch Neurol 2005; 62: 1345-56.
29. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain 2006; 129: 584-94.
30. Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis. Cochrane Database Syst Rev 2000; 4: CD001331.
31. Sharrack B, Hughes RA, Soudain S, Dunn G. The psychometric properties of clinical rating scales used in multiple sclerosis. Brain 1999; 122: 141-59.
32. Patzold T, Schwengelbeck M, Ossege LM, Malin JO, Sindern E. Changes of the MS functional composite and EDSS during and after treatment of relapses with methylprednisolone in patients with multiple sclerosis. Acta Neurol Scand 2002; 105: 164-8.
33. Foong J, Rozewicz L, Quaghebeur G, Thompson AJ, Miller DH, Ron MA. Neuropsychological deficits in multiple sclerosis after acute relapse. J Neurol Neurosurg Psychiatry 1998; 64: 529-32.
34. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.